These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 35152768)
21. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Dupuis-Girod S; Ambrun A; Decullier E; Samson G; Roux A; Fargeton AE; Rioufol C; Schwiertz V; Disant F; Chapuis F; Donazzolo Y; Paintaud G; Edery P; Faure F MAbs; 2014; 6(3):794-9. PubMed ID: 24481211 [TBL] [Abstract][Full Text] [Related]
22. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature. Arizmendez NP; Rudmik L; Poetker DM Int Forum Allergy Rhinol; 2015 Nov; 5(11):1042-7. PubMed ID: 26202958 [TBL] [Abstract][Full Text] [Related]
23. Development and Validation of the Nasal Outcome Score for Epistaxis in Hereditary Hemorrhagic Telangiectasia (NOSE HHT). Peterson AM; Kallogjeri D; Spitznagel E; Chakinala MM; Schneider JS; Piccirillo JF JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):999-1005. PubMed ID: 33022056 [TBL] [Abstract][Full Text] [Related]
24. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review. Stokes P; Rimmer J Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422 [TBL] [Abstract][Full Text] [Related]
26. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia]. Xu C; Wang HT Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 51(6):476-9. PubMed ID: 27345893 [TBL] [Abstract][Full Text] [Related]
27. New classification of nasal vasculature patterns in hereditary hemorrhagic telangiectasia. Mahoney EJ; Shapshay SM Am J Rhinol; 2006; 20(1):87-90. PubMed ID: 16539301 [TBL] [Abstract][Full Text] [Related]
28. Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis. Hsu YP; Hsu CW; Bai CH; Cheng SW; Chen C Otolaryngol Head Neck Surg; 2019 Jan; 160(1):22-35. PubMed ID: 30200816 [TBL] [Abstract][Full Text] [Related]
29. Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review. Halderman AA; Ryan MW; Clark C; Sindwani R; Reh DD; Poetker DM; Invernizzi R; Marple BF Int Forum Allergy Rhinol; 2018 Jun; 8(6):713-728. PubMed ID: 29393992 [TBL] [Abstract][Full Text] [Related]
30. Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients. Pagella F; Colombo A; Matti E; Giourgos G; Tinelli C; Olivieri C; Danesino C Am J Rhinol Allergy; 2009; 23(1):52-8. PubMed ID: 19379613 [TBL] [Abstract][Full Text] [Related]
34. Intranasal bevacizumab injections improve quality of life in HHT patients. Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573 [TBL] [Abstract][Full Text] [Related]
35. A silicone nasal swab for the treatment of severe and recalcitrant epistaxis in hereditary hemorrhagic telangiectasia: an alternative to surgical nostril closure. Bruschini L; Seccia V; Dallan I Am J Otolaryngol; 2011; 32(4):301-3. PubMed ID: 20719406 [TBL] [Abstract][Full Text] [Related]
36. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT). Zarrabeitia R; Albiñana V; Salcedo M; Señaris-Gonzalez B; Fernandez-Forcelledo JL; Botella LM Curr Vasc Pharmacol; 2010 Jul; 8(4):473-81. PubMed ID: 19485912 [TBL] [Abstract][Full Text] [Related]
37. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose. Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282 [TBL] [Abstract][Full Text] [Related]
38. Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT). Wirsching KEC; Haubner F; Kühnel TS Eur Arch Otorhinolaryngol; 2017 Apr; 274(4):1891-1896. PubMed ID: 28070641 [TBL] [Abstract][Full Text] [Related]
39. Long-term efficacy assessment of current treatment options for epistaxis in HHT. Dür C; Anschuetz L; Negoias S; Bulut OC; Angelillo-Scherrer A; Caversaccio M Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4321-4328. PubMed ID: 33661356 [TBL] [Abstract][Full Text] [Related]